To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024.
Impact
This legislation is significant as it alters the funding dynamics of pivotal programs designed to foster innovation and advancements in medical treatments and therapies. The Cures Act, enacted to support research and development, benefits greatly from federal funding; however, this bill poses a substantial cut that could hinder its efficacy. Supporters argue that such limitations are necessary for fiscal responsibility and to prevent government overspending, while opponents fear that insufficient funding could stall critical health advancements.
Summary
House Bill 2297 aims to enforce a limitation on the funding available for the Related Agency and the Food and Drug Administration (FDA) Innovation Account under the Cures Act for the fiscal year 2024. The proposed measure stipulates that the total amount appropriated or otherwise made available for these purposes shall not exceed $50 million. This bill reflects an effort to impose a strict budgetary constraint amid growing concerns about federal spending on healthcare initiatives.
Contention
Key points of contention surrounding HB 2297 include debates over the adequacy of funding for the FDA’s innovative efforts, particularly given the backdrop of ongoing health crises and the need for a robust healthcare infrastructure. Critics of the bill contend that capping FDA funding could compromise the agency’s capabilities to respond to public health emergencies and limit its role in fostering groundbreaking biomedical research. Proponents, on the other hand, defend the measure as a critical step towards a more fiscally responsible government that prioritizes budgetary limits over unrestricted healthcare spending.
To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Buildings and Facilities for fiscal year 2024.
To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Department of Health and Human Services, Food and Drug Administration, for fiscal year 2024.
To provide for a limitation on availability of funds for Department of Health and Human Services, National Institutes of Health Innovation Account, CURES Act for fiscal year 2024.
To provide for a limitation on availability of funds for Related Agencies, Railroad Retirement Board, Dual Benefits Payments Account for fiscal year 2024.
To provide for a limitation on availability of funds for US Department of Agriculture, Food and Nutrition Service, Nutrition Programs Administration for fiscal year 2024.